Highlights JCR Pharmaceuticals Co., Ltd.

Equities

4552

JP3701000006

Delayed Japan Exchange Other stock markets 20:54:00 2024-06-25 EDT			5-day change	1st Jan Change
594 ^JPY	-1.98%		+2.06%	-49.23%

06-24	JCR Pharmaceuticals Co., Ltd.(TSE:4552) dropped from S&P Japan 500	CI
05-31	JCR Pharmaceuticals' Full-Year Profit Up 46%	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

JCR Pharmaceuticals' Full-Year Profit Up 46%	05-31	MT
Jcr Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025	05-10	CI
Jcr Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Period Second Quarter and Full Year of Year Ending March 31, 2025	05-10	CI
JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2024, Payable on June 27, 2024	05-10	CI
Final dividend	03-27	FA
US Fed Rate Outlook Catapults Japanese Shares to Fresh 52-Week Peak	03-21	MT
JCR Pharmaceuticals Achieves Neurodegenerative Treatment Research Milestone With Alexion	03-20	MT
JCR Pharmaceuticals Co., Ltd. Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion	03-19	CI
JCR Pharmaceuticals Co., Ltd. Presents Clinical Data on J-Brain Cargo®? to Deliver Medicines Across the Blood-Brain Barrier	02-14	CI
JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	02-08	CI
JCR Pharmaceuticals' Partner Takeda to Scrap Gene Therapy Collaboration	12-21	MT
JCR Pharmaceuticals Co., Ltd. and Takeda Pharmaceutical Co., Ltd. Announces Discontinuation of Gene Therapy Collaboration	12-20	CI
JCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo	12-20	CI
Modalis Therapeutics, JCR Pharmaceuticals Form Drug Delivery Research Partnership	12-12	MT
Modalis Therapeutics Corporation and JCR Pharmaceuticals Enter into Joint Research Agreement	12-12	CI
Japanese Shares Rebound on Wednesday, Boosted by Automotive Stocks	11-22	MT
JCR Pharmaceuticals' Fiscal H1 Attributable Profit Climbs on Increased Drug Sales	11-21	MT
JCR Pharmaceuticals Co., Ltd. Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA	23-10-26	CI
JCR Pharmaceuticals Co., Ltd. Declares Interim Dividend for the Fiscal Year Ending March 31, 2024, Payable on December 8, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	23-10-25	CI
JCR Pharmaceuticals Co., Ltd. Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)	23-09-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights JCR Pharmaceuticals Co., Ltd.

Equities

4552

JP3701000006

Highlights

Filters